MCA logo

PUBLIC PORTAL

MEDICALLY REVIEWED

FDA approves lenacapavir (Sunleca®) in heavily pre-treated adults with multi-drug resistant HIV-1 infection

Lenacapavir, HIV
Lenacapavir (Sunleca®), a first-in-class long-acting HIV-1 capsid function inhibitor, was approved by the FDA in December 2022

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

physiotherapy
World Physiotherapy Day 2022

Get the best help for Osteoarthritis with the guidance of physiotherapists – #WorldPTDay World Physiotherapy Day (World PT Day) happens every year on 8 Sep.

Read More »